Indication
Peritoneal Cancer
53 clinical trials
52 products
11 drugs
Product
OregovomabClinical trial
A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal CarcinomaStatus: Active (not recruiting), Estimated PCD: 2025-09-26
Product
entinostatProduct
avelumabClinical trial
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-inStatus: Completed, Estimated PCD: 2019-02-21
Product
PlaceboProduct
CarboplatinProduct
PaclitaxelClinical trial
A Phase 2, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial Comparing Chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab) Versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) as Neoadjuvant Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal CarcinomaStatus: Recruiting, Estimated PCD: 2024-09-15
Product
NM21-1480Clinical trial
A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2024-02-06
Product
NiraparibClinical trial
Phase 2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Niraparib as a Combinatorial Immune Priming Strategy in Subjects With Platinum Sensitive Recurrent Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2024-03-30
Product
NM32-2668Clinical trial
A Phase 1 Study of NM32-2668 (Anti-ROR1/CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients With Selected Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2027-12-31
Product
RadspherinClinical trial
A Phase 1/2a Study to Evaluate the Dose, Safety and Tolerability and Efficacy of an Intraperitoneal α-emitting Radionuclide Therapy (Radspherin®) in Subjects With Peritoneal Carcinomatosis From Colorectal Carcinoma Following Hyperthermic Intraperitoneal ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2025-02-01
Product
Mirvetuximab soravtansineClinical trial
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)Status: Active (not recruiting), Estimated PCD: 2024-01-17
Clinical trial
Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (GLORIOSA)Status: Recruiting, Estimated PCD: 2027-03-01
Product
BevacizumabClinical trial
A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor MalignancyStatus: Terminated, Estimated PCD: 2024-04-15
Product
NivolumabProduct
Allocetra-OTSProduct
TislelizumabProduct
BP1001-AClinical trial
A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid TumorsStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
CATCH-R: A Rollover Study to Provide Continued Access to Clinical Therapy With RucaparibStatus: Completed, Estimated PCD: 2023-03-08
Product
RucaparibClinical trial
A Single-arm, Phase III Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Advanced High-grade Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer With High Expression of Folate Receptor-αStatus: Recruiting, Estimated PCD: 2023-04-30
Product
Mirvetuximab SoravtansineClinical trial
Phase I Study of Intraperitoneal Radioimmunotherapy With 131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the PeritoneumStatus: Terminated, Estimated PCD: 2019-06-11
Product
131 I-8H9Product
ChemotherapyClinical trial
ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus: Completed, Estimated PCD: 2020-12-03
Product
MirvetuximabClinical trial
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha ExpressionStatus: Completed, Estimated PCD: 2021-11-16
Clinical trial
A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With gBRCA Mutation Ovarian Cancer or Other Solid TumorStatus: Completed, Estimated PCD: 2019-03-01
Clinical trial
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian CancerStatus: Completed, Estimated PCD: 2018-05-14
Product
pembrolizumabProduct
niraparibClinical trial
A Phase I Trial Evaluating a Mutanome-directed Immunotherapy in Patients With High Grade Serous Carcinoma (HGSC) of the Ovary, Fallopian Tube or Peritoneum.Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
TG4050Clinical trial
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer ( ARIEL3 )Status: Completed, Estimated PCD: 2017-04-01
Clinical trial
A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)Status: Completed, Estimated PCD: 2019-11-05
Clinical trial
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense RegimenStatus: Completed, Estimated PCD: 2022-02-08
Product
Tisotumab VedotinClinical trial
KANDOVA - A Two-Part Phase Ib/IIa Study to Evaluate the Safety and Tolerability of KAND567, in Combination With Carboplatin Therapy, and to Determine the Recommended Phase II Dose (RPIID) of KAND567: An Open-Label, Multicenter Dose Escalation Study With an Expansion Cohort in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus: Recruiting, Estimated PCD: 2024-06-30
Product
ZN-c3Clinical trial
A Phase 1b Study of ZN-c3 in Combination With Chemotherapy in Patients With Platinum-Resistant Ovarian, Peritoneal or Fallopian Tube CancerStatus: Recruiting, Estimated PCD: 2024-01-31
Product
KAND567Product
GemcitabineClinical trial
A Pilot Study Investigating the Effect of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers of Mullerian OriginStatus: Completed, Estimated PCD: 2019-01-31
Product
PembrolizumabClinical trial
A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Drug
AtezolizumabClinical trial
Niraparib vs Niraparib in Combination With Bevacizumab in Patients With Carboplatinum-taxane Based Chemotherapy in Advanced Ovarian Cancer (A Multicentre Randomised Phase III Trial)Status: Recruiting, Estimated PCD: 2028-02-01
Drug
AN0025Drug
TiragolumabClinical trial
A Randomized Placebo-controlled Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2018-10-08
Product
KetorolacClinical trial
MT2021-27 Intraperitoneal FT538 With Intravenous Enoblituzumab in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerStatus: , Estimated PCD: 2026-09-30
Product
FT538Drug
EnoblituzumabClinical trial
A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2020-12-31
Product
SapanisertibClinical trial
A Phase II Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With HIPEC in Patients With Ovarian, Fallopian Tube or Primary Peritoneal CarcinomaStatus: Recruiting, Estimated PCD: 2024-08-31
Product
HIPEC with CarboplatinClinical trial
GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262Status: Active (not recruiting), Estimated PCD: 2015-12-01
Clinical trial
Feasibility Study of Neo-adjuvant Treatment With Carboplatin, Paclitaxel and Pembrolizumab in Primary Stage IV Serous Ovarian CancerStatus: Completed, Estimated PCD: 2023-06-01
Clinical trial
A Pilot Study of Wee1 Inhibition Induction Prior to Tumor Reductive Surgery in Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2026-12-31
Drug
AdavosertibClinical trial
COordinated Nivolumab and IntraperiToneal IL-2 for Gastric CanceR With PeritOneaL Metastasis (CONTROL) Phase 1b Pilot StudyStatus: Recruiting, Estimated PCD: 2026-01-01
Product
AldesleukinClinical trial
Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-12-01
Product
CisplatinDrug
5-FUProduct
LeucovorinDrug
mFOLFOX6Clinical trial
Feasibility Pilot Study of a Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) on Quality of Life for Ovarian Cancer Patients on Adjuvant ChemotherapyStatus: Recruiting, Estimated PCD: 2026-04-01
Product
AHCCDrug
CisplatinClinical trial
A Pilot Study of the Immunological Effects of Neo-Adjuvant INCB024360 in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CarcinomaStatus: Active (not recruiting), Estimated PCD: 2016-03-31
Product
EpacadostatClinical trial
A Multicentre Phase II Randomised Controlled Trial to Evaluate the Efficacy of Adaptive Therapy (AT) With Carboplatin, Based on Changes in CA125, in Patients With Relapsed Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian CancerStatus: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
A Phase II Randomized Study: Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian CancerStatus: Recruiting, Estimated PCD: 2029-12-01
Drug
ZEN003694Product
TalazoparibClinical trial
Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
Phase I Dose Escalation Study Evaluating the Safety of Adding Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Cisplatin-doxorubicin to the Systemic Chemotherapy, and the Recommended Phase II Dose, in Women With Insufficient Response to Carboplatin-paclitaxel for Advanced Epithelial Cancer of the Ovary, Fallopian Tubes or PeritoneumStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Phase II Combination of 131I-Omburtamab Radioimmunotherapy and External Beam Radiotherapy for Desmoplastic Small Round Cell TumorStatus: Recruiting, Estimated PCD: 2024-07-01
Product
131 I-omburtamabClinical trial
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube CancerStatus: Recruiting, Estimated PCD: 2026-04-15
Drug
olaparibClinical trial
Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant ChemotherapyStatus: Terminated, Estimated PCD: 2022-09-01
Clinical trial
Efficacy and Safety of Huaier Granule in Patients With Stage I Primary Ovarian Fallopian Tube Cancer After Peritoneal Cancer: a Single-center Prospective Single-arm StudyStatus: Not yet recruiting, Estimated PCD: 2023-12-01
Product
HuaierClinical trial
Phase II Trial of Maintenance Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2025-03-17
Clinical trial
Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing CancersStatus: Active (not recruiting), Estimated PCD: 2025-03-01
Product
huCART-mesoClinical trial
Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Ovarian, Fallopian Tube, and Peritoneal CancerStatus: Recruiting, Estimated PCD: 2024-06-01
Product
MicrodeviceClinical trial
Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superiority StudyStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase I Study of Intraperitoneal 5FU+Oxaliplatin in Patients With Colorectal Cancer With Isolated Peritoneal MetastasisStatus: Recruiting, Estimated PCD: 2025-12-31
Drug
fluorouracil